1-3 of 3
John Lambert, MD
Close
Sort by
Journal Articles

An Open Label, Dose Escalation Study of AVE9633 Administered as a Single Agent by Intravenous (IV) Infusion Weekly for 2 Weeks in 4-Week Cycle to Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).

Ollivier Legrand, MD, Maria B. Vidriales, MD, Xavier Thomas, MD, Charles Dumontet, MD, Anne Vekhoff, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Jesus F. San Miguel, MD, Jean-Pierre Marie, MD
Journal: Blood
Blood (2007) 110 (11): 1850.
https://doi.org/10.1182/blood.V110.11.1850.1850
Published: 2007
Journal Articles

Phase I Study of AVE9633, an AntiCD33-Maytansinoid Immunoconjugate, Administered as an Intravenous Infusion in Patients with Refractory/Relapsed CD33-Positive Acute Myeloid Leukemia (AML).

Francis Giles, MD, Rodica Morariu-Zamfir, MD, John Lambert, MD, Srdan Verstovsek, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Dan Deangelo, MD
Journal: Blood
Blood (2006) 108 (11): 4548.
https://doi.org/10.1182/blood.V108.11.4548.4548
Published: 2006
Journal Articles

Hematide™, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Demonstrates Erythropoietic Activity in a Phase 2 Single Dose, Dose Escalating Study in Patients with Chronic Kidney Disease (CKD).

Anne-Marie Duliege, MD, Iain Macdougall, MD, Neill Duncan, MD, Dawie Wessels, MD, Julie Iwashita, Pete Schatz, PhD, Robert Naso, PhD, Richard Stead, MD, John Lambert, MD
Journal: Blood
Blood (2005) 106 (11): 3532.
https://doi.org/10.1182/blood.V106.11.3532.3532
Published: 2005